Complete Tirzepatide Research Guide: GLP-1/GIP Dual Agonist

What Is Tirzepatide?

Tirzepatide (internal designation GLP-2 T in research catalogues) is a 39-amino acid synthetic peptide that functions as a dual agonist at two Class B G-protein coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is the first pharmacological agent designed to co-activate both incretin hormone receptors simultaneously.

CAS Number: 2023788-19-2 Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈ Molecular weight: 4,813.5 Da Half-life: ~5 days (120 hours) Available vial sizes: 15mg, 20mg, 30mg, 60mg

Structural Biology

Tirzepatide's structure is based on the native GIP sequence backbone, with four critical modifications:

1. Aib at Position 2 (DPP-4 Resistance)

Native GIP and GLP-1 are rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) at the His-Ala bond between positions 1-2. Tirzepatide substitutes α-aminoisobutyric acid (Aib) at position 2 — a bulky, non-standard α,α-disubstituted amino acid that creates steric hindrance blocking DPP-4 access. This single modification extends metabolic half-life from ~7 minutes (native GIP) to hours.

2. C20 Fatty Diacid at Lys26 (Half-Life Extension to 5 Days)

The C20 eicosanedioic acid is attached to Lys26 via a γGlu-2xOEG linker. This lipophilic chain enables reversible, non-covalent binding to serum albumin (~70 kDa protein present at ~35-50 g/L in plasma). Albumin-bound tirzepatide is protected from renal filtration (albumin is far too large for the glomerular filtration barrier) and from proteolytic enzymes. The binding is reversible — tirzepatide cycles between free (pharmacologically active) and albumin-bound (pharmacokinetically stabilised) states, extending half-life to ~5 days and enabling once-weekly dosing.

3. Selective Receptor Affinity Profile

The sequence modifications also tune receptor affinities:

• GIPR: ~native GIP affinity (full agonist)
• GLP-1R: ~5-fold lower affinity than native GLP-1, but the extended half-life compensates — sustained receptor engagement over 5 days delivers net GLP-1R activation equivalent to high-dose short-acting GLP-1 analogues

4. Aib at Position 13

A second Aib substitution at position 13 provides additional protease resistance and influences the helical conformation of the peptide, optimising receptor engagement geometry.

Mechanism of Action

GLP-1 Receptor Pathway

GLP-1R activation by tirzepatide produces:

• Glucose-dependent insulin secretion: β-cells secrete insulin only when blood glucose is elevated — inherent hypoglycemia safety
• Glucagon suppression: α-cell glucagon secretion is reduced, decreasing hepatic glucose output
• Gastric emptying delay: Reduces post-prandial glucose spikes by slowing nutrient absorption
• Central satiety: Hypothalamic and brainstem GLP-1R activation increases satiety signalling, reduces meal size and frequency
• Cardioprotection: GLP-1R in cardiomyocytes and endothelium; anti-inflammatory, anti-apoptotic effects

GIP Receptor Pathway

GIPR activation adds:

• Adipocyte lipolysis: In the context of metabolic, GIPR activation drives fatty acid mobilisation from adipose depots — preferentially visceral adipose tissue (VAT)
• β-cell protection: GIPR-mediated PI3K/Akt signalling reduces β-cell apoptosis
• Bone metabolism: GIPR in osteoblasts — relevant in long-duration protocols
• CNS synergy: GIPR co-activation in the hypothalamus potentiates GLP-1R satiety signals — supra-additive appetite suppression
• Nausea attenuation: GIPR in the area postrema counteracts GLP-1R-mediated emetic signalling

SURMOUNT Trial Summary

The four pivotal SURMOUNT trials in obesity represent the most successful obesity pharmacotherapy research program in history:

Trial

Population

N

Max Dose

Duration

Body Weight Reduction

SURMOUNT-1	Obesity, no T2DM	2,539	15mg	72 weeks	−22.5%
SURMOUNT-2	Obesity + T2DM	938	15mg	72 weeks	−15.7%
SURMOUNT-3	Post-lifestyle intervention	806	15mg	72 weeks	−26.6%
SURMOUNT-4	Maintenance extension	670	15mg	52 wks ext	Maintained

Key SURMOUNT-1 response rates at 15mg:

• 96% achieved ≥5% body weight reduction
• 91% achieved ≥10%
• 57% achieved ≥20%
• 36% achieved ≥25%

SURPASS Trial Summary

Eight Phase 3 glycaemic trials in T2DM (SURPASS 1-8):

• SURPASS-2 (vs semaglutide 1mg, N=1,879): Tirzepatide 15mg HbA1c reduction −2.46% vs −1.86% for semaglutide
• SURPASS-CVOT (vs semaglutide 1mg, N=13,884, 4 years): 15% MACE reduction with tirzepatide (HR 0.85, p<0.001 superiority)
• SURPASS-4 (vs insulin glargine): HbA1c −2.58% vs −1.44%; weight −10.9 kg vs +2.9 kg

Reconstitution Protocol

Required Materials

• Tirzepatide vial (lyophilized powder)
• Bacteriostatic water (0.9% benzyl alcohol) — do NOT use sterile water
• 18-21G needle for drawing up BAC water
• 28-31G ½-inch insulin syringe for dosing
• Alcohol swabs

Step-by-Step Protocol

• Remove vial from freezer and allow to reach room temperature over 30-60 minutes (sealed)
• Wipe rubber stopper with alcohol swab; allow to dry
• Draw up calculated volume of BAC water with a larger-gauge needle
• Insert needle through rubber stopper at an angle to avoid creating vacuum
• Slowly inject BAC water down the inside glass wall — do not spray directly onto the powder cake
• Remove needle; gently roll vial between palms for 30-60 seconds (do NOT shake — causes aggregation)
• Inspect: solution should be clear to slightly opalescent with no particles
• Label vial with reconstitution date and concentration

Concentration Reference

Vial

BAC Water

Concentration

5mg dose

10mg dose

15mg dose

15mg	1.0 mL	15 mg/mL	0.33 mL	0.67 mL	1.0 mL
20mg	1.0 mL	20 mg/mL	0.25 mL	0.5 mL	0.75 mL
30mg	2.0 mL	15 mg/mL	0.33 mL	0.67 mL	1.0 mL

Storage Post-Reconstitution

• Store at 2–8°C (standard refrigerator)
• Use within 28 days of reconstitution
• Do not freeze reconstituted solution
• Protect from light

Safety Profile

Based on SURMOUNT Phase 3 data (N>5,000 treated subjects):

Common adverse events (all dose-related, diminish after reaching maintenance dose):

• Nausea: 31% (tirzepatide 15mg) vs 9% (placebo)
• Diarrhea: 23% vs 7%
• Vomiting: 16% vs 4%
• Constipation: 11% vs 4%

Serious adverse events:

• Acute pancreatitis: 0.2% (not significantly different from placebo)
• Cholelithiasis (gallstones): increased risk with significant metabolic (class effect for all obesity treatments)
• No liver toxicity at any dose
• No signal for thyroid C-cell tumors in human trials (rodent-only signal with GLP-1 agonists)

Hypoglycemia: Rare as monotherapy (<1%) due to glucose-dependent mechanism. Risk increases with concomitant insulin use.

Research Applications

Tirzepatide research is currently active in:

• Metabolic syndrome research: Comprehensive cardiometabolic risk factor reduction
• NASH/NAFLD: Hepatic fat reduction, fibrosis regression
• Cardiovascular outcomes: SURPASS-CVOT superiority vs semaglutide
• Heart failure: SUMMIT trial — HFpEF outcomes
• Sleep apnea: SURMOUNT-OSA — AHI reduction
• Chronic kidney disease: eGFR preservation, albuminuria reduction
• Polycystic ovary syndrome (PCOS): Insulin sensitisation, metabolic
• Adipose tissue biology: VAT vs SAT remodelling, adipokine changes